Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Saquinavir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 2/20 | 1.00 |
| ▸ | TACR2 | P21452 | 2/20 | 1.00 |
| ▸ | TBXAS1 | P24557 | 2/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | AVPR1A | P37288 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | CACNA1D | Q01668 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Saquinavir SCHEMBL29534530 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC4ABCB11ABCB1TACR2 | |
| Saquinavir SCHEMBL1176566 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC4ABCB11ABCB1TACR2 | |
| Saquinavir SCHEMBL13575784 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC4ABCB11ABCB1TACR2 | |
| Saquinavir SCHEMBL1976548 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC4ABCB11ABCB1TACR2 | |
| Saquinavir SCHEMBL20451344 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC4ABCB11ABCB1TACR2 | |
| Saquinavir SCHEMBL8584255 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC4ABCB11ABCB1TACR2 | |
| Saquinavir SCHEMBL8584252 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC4ABCB11ABCB1TACR2 | |
| Saquinavir SCHEMBL13953012 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC4ABCB11ABCB1TACR2 | |
| Saquinavir SCHEMBL21683360 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC4ABCB11ABCB1TACR2 | |
| Saquinavir SCHEMBL29357501 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC4ABCB11ABCB1TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 43534 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| EP-4094767-B1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-20 | — | — | EP | claimed |
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| WO-2026102345-A1 | METHODS OF ADMINISTERING THE VOLTAGE-GATED POTASSIUM CHANNEL OPENER AZETUKALNER | XENON PHARMACEUTICALS INC. (CA) | 2026-05-15 | — | — | WO | claimed |
| US-20260124290-A1 | HIV Immunogens, Vaccines, and Methods Related Thereto | UNIV EMORY (US) | 2026-05-07 | — | — | US | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| WO-2026085583-A1 | MOLECULAR ASSAY FOR DETECTING HIV-1 DRUG-RESISTANT MUTATIONS | ST VINCENT'S HOSPITAL SYDNEY LIMITED (AU) | 2026-04-30 | — | — | WO | claimed |
| WO-2026086804-A1 | MULTILAYER-REGULATED GENE EDITING SYSTEM AND USE THEREOF | 自如基因科技（深圳）有限公司 | 2026-04-30 | — | — | WO | claimed |
| CN-1132756-A | Antiviral ethers of aspartate protease substrate isosteres | CIBA GEIGY AG (CH) | 1996-10-09 | — | — | CN | claimed |
| EP-0728481-A2 | Use of quinoxaline and protease inhibitors in a composition for the treatment of AIDS and/or HIV infections | BAYER AG (DE) | 1996-08-28 | — | — | EP | claimed |
| WO-1996022368-A1 | RIBOZYMES TARGETING THE RETROVIRAL PACKAGING SEQUENCE EXPRESSION CONSTRUCTS AND RECOMBINANT RETROVIRUSES CONTAINING SUCH CONSTRUCTS | GENE SHEARS PTY. LTD. (AU) | 1996-07-25 | — | — | WO | claimed |
| EP-0432694-B1 | Aminoalcohols | HOFFMANN LA ROCHE (CH) | 1996-05-29 | — | — | EP | claimed |
| WO-1996010399-A1 | LIPOSOME-FORMULATIONS FOR TREATMENT OF VIRAL DISEASES | BERGERON MICHEL G (CA) | 1996-04-11 | — | — | WO | claimed |
| US-5484801-A | Pharmaceutical composition for inhibiting HIV protease | ABBOTT LABORATORIES (US) | 1996-01-16 | — | — | US | claimed |
| WO-1995024385-A1 | SULPHONAMIDE DERIVATIVES AS ASPARTYL PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1995-09-14 | — | — | WO | claimed |
| EP-0432695-B1 | Amino acid derivatives | HOFFMANN LA ROCHE (CH) | 1995-05-17 | — | — | EP | claimed |
| US-5196438-A | Viricides; e.g. N-tert.butyl-decahydro-2-(2(R)-hydroxy-4-phenyl-3(S)-((N-(2 -quinolylcarbonyl)-L-asparaginyl)amino)butyl)-(4aS,8aS)-isoquinoline-3(S) -carboxamide; saquinavir and salts | HOFFMANN-LA ROCHE INC. (US) | 1993-03-23 | — | — | US | claimed |
| EP-0432695-A2 | Amino acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1991-06-19 | — | — | EP | claimed |